News coverage about Bristol-Myers Squibb (NYSE:BMY) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Bristol-Myers Squibb earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 44.5626324975649 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the media headlines that may have impacted Accern Sentiment’s analysis:
- Citigroup Reiterates $78.00 Price Target for Bristol-Myers Squibb (BMY) (americanbankingnews.com)
- Bristol-Myers Squibb (BMY) in Focus: Stock Moves 5.6% Higher (finance.yahoo.com)
- 3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb (finance.yahoo.com)
- BMY INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Bristol-Myers Squibb Company (finance.yahoo.com)
- With A -77.41% Earnings Drop Lately, Did Bristol-Myers Squibb Company (NYSE:BMY) Underperform Its Industry? (finance.yahoo.com)
Several research firms recently commented on BMY. Piper Jaffray Companies restated a “hold” rating and set a $60.00 price target on shares of Bristol-Myers Squibb in a report on Friday, October 27th. Citigroup set a $78.00 price target on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a report on Friday. Vetr upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating and set a $60.72 price target for the company in a report on Thursday, February 1st. Leerink Swann raised their price target on shares of Bristol-Myers Squibb from $71.00 to $76.00 and gave the stock a “positive” rating in a report on Tuesday, February 6th. Finally, BMO Capital Markets decreased their price target on shares of Bristol-Myers Squibb from $52.00 to $51.00 and set an “underperform” rating for the company in a report on Tuesday, February 6th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $66.73.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, beating the Zacks’ consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. The company had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.35 billion. During the same quarter last year, the firm posted $0.63 earnings per share. The company’s quarterly revenue was up 3.9% compared to the same quarter last year. analysts expect that Bristol-Myers Squibb will post 3.21 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Thursday, February 1st. Stockholders of record on Friday, January 5th were given a $0.40 dividend. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Thursday, January 4th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.32%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 67.80%.
In other news, EVP Thomas J. Jr. Lynch sold 5,300 shares of Bristol-Myers Squibb stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total value of $335,172.00. Following the transaction, the executive vice president now owns 9,251 shares of the company’s stock, valued at $585,033.24. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Theodore R. Samuels II purchased 4,000 shares of the company’s stock in a transaction dated Friday, December 15th. The stock was purchased at an average cost of $62.30 per share, for a total transaction of $249,200.00. Following the transaction, the director now owns 22,000 shares of the company’s stock, valued at $1,370,600. The disclosure for this purchase can be found here. Company insiders own 0.23% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.